Saturday 17 October 2026
Export LXEO’s income statement to Excel — free account
Lexeo Therapeutics, Inc.
LXEO Healthcare Biotechnology
Lexeo Therapeutics, Inc.’s revenue for fiscal 2022 (year ended December 2022) was $654,000.00. In the quarter to June 2026, EPS grew 50.0%, free cash flow grew 35.6% and total debt fell 83.5%, each against the same quarter a year earlier.
2.64
0.12
−4.35%
Follow LXEO
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
| (46.76%) | (54.75%) | (55.00%) | (80.69%) |
+8 more TTM periods Free account |
|
| (40.50%) | (46.54%) | (48.10%) | (66.08%) | ||
ROIC |
(253.48%) | (158.12%) | (104.69%) | 0.00% | |
Return on Tangible Assets |
(42.92%) | (46.60%) | (57.87%) | (93.93%) | |
Free Cash Flow per Share |
(1.04) | (1.21) | (1.84) | (1.76) | |
Free Cash Flow |
(88.70) | (98.42) | (98.96) | (107.29) | |
Capital Expenditures |
(0.33) | (0.43) | (0.40) | (0.48) | |
| Other line items | |||||
Cash ROIC |
(19.85%) | (23.17%) | (23.08%) | (43.96%) | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Interest Coverage |
(1,302.97) | (1,164.11) | (1,150.07) | (1,081.17) | |
Operating CF/Net income |
1.01 | 1.12 | 0.99 | 1.02 | |
Depreciation/Fixed assets |
0.30 | 0.31 | 0.33 | 0.29 | |
Capex/Depreciation |
(0.98) | (1.28) | (1.05) | (1.36) | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(1.03) | (1.21) | (1.84) | (1.75) | |
Capex per Share |
0.00 | (0.01) | (0.01) | (0.01) | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 |
Columns are period end dates